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Abstract
The great advantage of being a sexually transmitted disease is the ability to survive and specialize
solely on a host species that is present in low numbers and widely distributed so that contact
between infected and uninfected organisms by chance is rare.
Pathogens of a sparse, but widely distributed host species, must either: i) have an alternative host;
ii) be able to survive in a dormant state; or iii) be non-destructive to their host. For the pathogens
of a diploid there is a particularly effective strategy, that of being sexually transmitted. Then the
hosts' themselves transfer the pathogen.
Sexually Transmitted Diseases
The advantages of this mode of pathogenic transmission
are clear, but the great disadvantage is that evolution has
now produced many very sophisticated mechanisms in
the host to block pathogens of various origins and special-
ties from entering and growing effectively in the sexual
apparatus of the female mammal.
Thus, the biological problems that STD mechanisms face
are because of the countermeasures against the pathogens
that are due to evolution of the host. However, the mech-
anisms that have developed that protect the fetus from the
host's immune system do help the STP.
Problems with the STD approach from its point of view
There are two major problems with the STD strategy: First,
a sexually transmitted disease must be (at least relatively),
a 'gentle pathogen' or a 'prudent predator' and remain as
such (i.e., it may only evolve towards greater virulence
slowly, or not at all). Secondly, such a pathogen must, to
a large extent, be able to avoid destroying its mammalian
host's offspring before the child grows to a sexual adult
stage. Both factors would seemingly be countermanded by
the immediate selective advantage of being more virulent
and producing more propagules.
The Vertebrate's Female Reproductive Tract (FRT)
The immune system of the mammalian sexual system has
many wonderful properties because of the many prob-
lems that the Female Reproductive Tract (FRT) faces. The
immune system of the FRT is nonpareil for its diverse abil-
ities to solve these problems. Possible pathogens include
a large range of viruses, bacteria, and protozoa. Mostly
these are destroyed or eliminated by the FRT. Addition-
ally, when there is an embryo: this propagule is foreign
because half its genes are not derived from the mother.
The mechanisms of the FRT must not operate against it.
Although, it is a foreign object like all the pathogens of the
host, this particular entity is to be protected.
The Fetus is Special
Consider a Sexually Transmitted Disease (STD) from the
pathogen's point of view: it must successfully pass into the
female sexual tract, possibly into her body, and into the
next adult generation of hosts. So the STD faces a quite
different fate than other kinds of pathogens.
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Advantages of Vertical Transmission
To reiterate the virtue from the pathogens' point of view,
the STD strategy is favorable because the pathogen is
propagated to new hosts without entering the environ-
ment. Thus, the infection of a new host is expedited by the
old host's behavior in searching for mates, and thus many
mechanisms used by other pathogens for transmission are
not needed.
Complications of the Many Roles in the Female Sexual 
Tract
The FTR is a complex of organs: ovary, fallopian tubes,
uterus, cervix, and vagina. They have many physiological
aspects that are quite different from each other and each is
essential for the propagation of the host species. They, of
course, all do act in a way favorable for reproduction, but
unfavorable, at various degrees, to pathogens. But the
STD's are treated quite differently.
Consequence of the Absence of an Immune System in the 
Fetus and Newborn
The lack of an effective immune system in the fetus (even
in the presence of maternal passive immunity) and in the
newborn (even given mother's milk with colostrum)
implies that the STD pathogens might propagate in utero
even though the mucosal immune system of the female
sexual tract may be able to reduce the danger of infection
and disease to many disease agents to the offspring.
Importance of Protecting the Fetus, the Neonate, and the 
Pre-pubescence Child
In the long run, with many ins-and-outs, the current situ-
ation is favorable for the STD pathogens because the long
term interest of the host species is that the young mem-
bers of the host population grow to become sexually
mature and this provides hosts to become infected and
propagate the pathogen.
Stone age life
When populations of humans arose and expanded and
emigrated in the early Stone Age, the problem that patho-
gens would have of how to propagate and surviving in this
sparse host population became critical. Cave-dwelling
primitive humans, 30 thousand years ago that lived in
small well-separated tribal populations would have had
quite different diseases than humans have today. Worka-
ble disease possibilities are few but would include, sexual
transmitted diseases. However, this required that the
pathogens were 'gentle' to their host. Other possibilities
for these pathogens are either: acquiring and using an
ability to remain dormant for long periods of time or of
being able to infect a ubiquitously occurring alternative
species. These latter two possibilities will not be examined
further here, but they do occur in nature. The option of
being 'gentle' to the fetus is the main topic here with
respect to STDs, but a further aspect of this will also be
presented; this is that an STD of a mammal will face the
special problems of preventing the destruction of the
fetuses and neonates of its host because these are needed
for its own propagation.
The Advantage of being an STD in a Sparsely Populated 
World
There is an essential feature needed for a successful infec-
tious disease of social animals that are distributed in dis-
persed state in individual groups with small numbers.
This is to have a way to spread from social group to social
group. In sundry diseases [1-4], this is done by forming
long-lived spores, or passing through intermediate hosts
or vectors, or being carried by various animal and insect
vectors over significant distances. Another very effective
and quite successful way, however, is to use a sexual mode
of transmission, which depends on the host actively inter-
acting with spatially remote populations of hosts. In gen-
eral, many STD pathogens are not long lived within the
environment outside the host's body. In addition, they are
usually highly specific so that they do not have an alter-
nate host (except only very rarely); consequently before
the invention of the hypodermic needle, these STD dis-
eases usually had only a sexual mode of transmission
within the individuals of a species [5-9]. STDs must be
extremely common since there are many viruses that are
quite mild (Hoeprich et al. [1]) and I assume that there are
many more such agents that are so mild that they have not
been detected.
Depending on the degree of interaction between social
groups, this strategy would be unsuccessful if the patho-
gen was highly lethal and the host populations widely dis-
tributed, since they would be eliminated from a local
population by destruction of subpopulations and usually
not be successful in reaching neighboring communities.
This is the way, I presume, that ebola was in rural Africa in
the past: it arose from some animal into a human social
group, destroying that group, then the viruses were elimi-
nated, ending that particular episode. Consequently, any
successful STD disease would need to be as 'gentle' as pos-
sible while still retaining its infectiousness, if it is to be
effectively transmitted to other hosts during rare encoun-
ters between groups when population levels are low and
well separated.
A distinction needs to be made from a mechanism that
differentiates survival of a 'gentle pathogen' from the evo-
lution of the pathogen as the results of group selection.
Group selection occurs, for instance, if there is the possi-
bility that some pathogen may contain or acquire a gene
that confers some advantage or level of resistance to the
pathogen. This gene and its population would then beVirology Journal 2008, 5:93 http://www.virologyj.com/content/5/1/93
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selected because pathogens with that gene would prosper
and become dominant.
The long-term persistence of a disease among sparsely dis-
tributed social animals would depend on the particulars
of the social interaction between groups. Passage of a STD
from group to group is aided by the social behavior of the
hosts, which may institutionalize transfer. For example,
the social groups of many kinds of mammals' centers
around a single dominate male or a female of a bonded
social group [9-13]. Consequently, other (usually
younger) males or females of a variety of species are
ejected from their natal small groups. Sometimes these
may become the dominant in other groups. However,
they may incidentally carry STDs with them.
In chimpanzee troops and other primates living in groups
there is often the exchange of young females between
groups as the females reach sexual maturity. In many
cases, these females are forced to leave their original
group. Possibly this same strategy was practiced by early
human groups. After the female chimpanzees emigrate,
they are taken into neighboring colonies, spreading STDs.
Not only is this mixing of populations known from direct
observation of various non-human primate species, but it
also can be deduced by the smaller degree of polymor-
phism for genetic markers exhibited in the male popula-
tion of a clan of chimpanzees relative to the females in the
same group.
This process of exchange may serve the primate species
very well by limiting the effects of inbreeding. The expla-
nation of these behaviors by geneticists and sociobiol-
ogists is that consanguinity is bad for any species (except
obligatorily selfing-organisms, like Mendel's garden peas
that do practice incest habitually). Whatever the validity
of this explanation and how the custom arose, sexual mix-
ing occurs between social groups as an institutionalized
process even in the absence of prostitution, rape, and war.
Even if these violent transmission events between host
groups may be fairly infrequent they, and the less violent,
custom-justified, mixing between social groups are essen-
tial to the STD's way of life.
Diseases in primitive humans
A sexually transmitted disease gains most of the advan-
tages of vertical transmission in not needing to be trans-
mitted through the environment. Moreover and very
importantly, it can survive in sparse populations because
of its host's sexual proclivities. In these two sentences the
essential elements for a parasite (especially a virus) to sur-
vive by infecting humans as its only host in the Stone Age
have been spelled out. In such circumstances it was neces-
sary for a pathogen to be able to compensate for the low
population density and sporadic distribution of its host.
During the tail end of the most recent Ice Age, the human
hosts survived in small, mostly isolated, groups that figu-
ratively chased mastodons and other big game as a group
effort.
Those pathogens that depend on humans as a resource
faced a much different problem after domestication of
plants and animals than during the hunter/gatherer Stone
Age culture. Tuberculosis did occur in people in the
ancient Egyptian empire, but by then the population was
locally quite dense and transmission through the air from
person to person in large populations became efficient.
The problem of pathogens became still quite different
during the Industrial Revolution and in the medically
sophisticated world of today. Possibly, at the time of
Christ the world population was a thousand-fold larger
than during the Ice Age, and probably, the world popula-
tion of humans has increased more than a thousand-fold
since. Today, with the world human population
increased, with transportation easier, with higher local
population densities, with more rapid migration, and
with mixing of humanity taking place at an unprece-
dented rate the situation is entirely altered. These changes
must result in a great increase and alteration of the spec-
trum of diseases, and particularly of communicable dis-
eases that are transmitted effectively between people that
are crowded closely together. For this reason, it can be
argued that the major diseases of Stone Age humans were
largely STDs (or with those pathogens capable of remain-
ing dormant or propagating in other hosts) and the typi-
cal major infectious epidemic diseases experienced in the
early Christian era and afterwards were not. The aftermath
of hypodermic needles, jet planes, and other modern
inventions are that the spectrum of diseases has become
much different still.
The two keys of the matter are: first, that many of today's
STDs have had a long association with primates, includ-
ing humans, and have had an opportunity to modify their
hosts; and in return, the pathogens have been modified by
their host's biology. Second, the same group-group inter-
actions, as in the hunter/gatherer cultures described
above, apply to other primate populations living in the
wild today. So we can assume that STDs specializing in
particular species have been around for a very long time in
human and other primates populations, and that they
should generally be 'well-tuned' to their host species' par-
ticular sociality. Furthermore it can be assumed, that only
occasionally will such adapted STDs be dangerous or
lethal to their specific host species, or at least to a fraction
of the individuals of that population. To the degree that
HIV has recently entered the human population or more
specifically into the population of a some times medically
treated, modern, industrialized, jet age men and women,Virology Journal 2008, 5:93 http://www.virologyj.com/content/5/1/93
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it is now in an unfamiliar milieu and is especially danger-
ous (Gilbert [2]).
The strategy of cave man's diseases and those of 
modern primates
All STD's of cave men (I presume) and today's wild pri-
mates face the same general problems. But here we will be
more specific and consider the problems of the retroviral
STDs of monkeys and man [10-14]. Now let us match the
retroviruses of primates to the design criteria for a STD
pathogen of sparse populations. Point by point these cri-
teria are met by viruses abundant in non-human primate
populations in Africa today, such as SIV (Simian Immun-
odeficiency Virus) that is resident in the African Green
Monkey. Of course, SIV may be more virulent when trans-
ferred to different monkeys; e.g., to the geographically dis-
tant Asian ones, than the species from which it was
initially isolated. Of course, SIV would be virulent in ani-
mals that happen to have a defective immune system. The
general point is that the small deviation from its behavior
that has been optimized for a retroviruses' life in its native
host now may lead to catastrophic problems in the variant
host, whether it is the human, the Asian monkey, or the
compromised host.
It is assumed that HIV emigrated to humans relatively
recently; see [15-21] (and it is thought that 1930 was in
time of transmission to man from primate in the Belgian
Congo [20]. This virus and its new human hosts have not
had a chance to adapt genetically to each other though
there are some indications that there have been develop-
ments in this direction (Ewald [21]). One of the mis-
matches between the disease and its human host that
most affects disease virulence is that the immune system
after HIV infection of the human being deteriorates in 5 to
15 years; this same period would be unimportant to non-
human primate populations in the wild because they have
shorter mean life-spans and maturation periods and may
generally die of other causes before they lose their effec-
tive immune system. On this basis, it may be that the
changes needed to re-establish the 'gentle' parasite mode
in the new human hosts of SIV are minimal: For example,
just a shortening of the human life span to that of the turn
of the nineteenth century level would do. A disturbing,
but realistic, suggestion of a change that would certainly
make HIV infection relatively more 'gentle' is a general re-
emergence of life-shortening infectious diseases, such as
tuberculosis. There are many other diseases that may
erupt as the antibiotic era closes, and with the loss of effi-
cacy of antibiotics, the human life span may decrease dra-
matically and the immune system may survive to the end
of the life-span and outlasts the shortened length of life-
span of its host as the result of deaths from other causes
than just the effects of the AIDS. Then there would be a
lower proportion of individuals with signs of ARC or
AIDS. Changes of the other kinds will be suggested below
that might increase the longevity of the immune system in
an AIDS-infected individual in a long-lived population,
but other possible changes might decrease it.
The mucosal immune system
Of the many kinds of immunological responses, the ones
that function at mucosal surfaces are most relevant to
STDs during their transmission from individual to indi-
vidual [22-40] The feature relevant to STDs epidemiology
is that the female sexual tract is the right place for ways to
prevent new infections.
Immunology of the female reproductive tract
In order to be propagated, a sexually transmitted disease
needs to grow and be transmitted through both the
female and male reproductive tracts to new hosts. On the
other hand, particularly the female productive tract has
evolved mechanisms to overcome pathogens that enter it.
However, an important additional component for the dis-
ease is that the STD's somehow needs to ensure that the
embryo, fetus, and child of its host do not die, but grow
to sexual adults so that they too can serve as habitats for
STD to grow. "Ensure" is too strong a word as long as the
pathogen is only successful in attacking a small portion of
the host population.
Evidently, there are mechanisms contributed from both
the human and the virus to protect the juvenile against
destruction by the HIV, beginning at conception and con-
tinuing on to near adulthood. This is because otherwise
the fetus and neonate would be destroyed before leading
to an adult that can receive and propagate the virus.
The complex immunological processes within the preg-
nant female are indeed very sophisticated. This has been
well studied because the interest in this question is high
since this may be a possible basis for the prevention of the
spread of AIDS. It was, and is hoped, that immunological
ways could be developed. However, here the interest is to
try to understand the biology to the host-parasite interac-
tion from the point of view of the disease process. There
must be some blockade to transmission extent now
because even though HIV infection through sexual contact
of adult-to-adult is efficient, there are some fetuses and
children that are not infected or killed by the infection,
but grow up to become adults to be reservoirs for growth
and propagation of the virus.
A strong indicator that HIV is usually prevented from
infecting children perinatally is that while the majority of
children born to HIV-positive mothers are not infected,
they almost all carry maternal antibodies against HIV 41
(McWhinney, Pagano, and Thomas. [40]). PresumablyVirology Journal 2008, 5:93 http://www.virologyj.com/content/5/1/93
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they had them when in utero, but either had not become
infected or had overcome it.
Going even farther out on a limb, one can imagine that
the mucosal immune response could protect the baby
during the birthing process [41]. This might be accom-
plished by a strong IgA or T-cell response, or by an IgG
response that is delivered through the placenta [42]. If this
were possible in terms of the host's immunological reper-
toire modulated by some stimulatory action of the patho-
gen, this would increase the long-term fitness of the STD.
Such a situation would lead to continued selection for
such genetic variants of the host and/or in the STD. Then
of course, through successive generations of virus and
host in an environment with high levels of other patho-
gens, these developments would 'tune' the growth of the
particular retrovirus to a particular primate species. These
changes may lead to effective prevention of infection due
to secondary pathogens or due to superinfection of the
resident sexual disease by other copies of itself, and would
have a long term (and incidental effect of maintaining the
host population). Such selection would lead to corre-
sponding changes so that the pathogen becomes milder to
the host as a consequence of induction of greater immu-
nogenicity against the resident pathogen and would be
beneficial to the host because the first pathogen would
prevent other, possibly more dangerous pathogens, from
entering and destroying it.
The converse possibility is that the pathogen causes dele-
terious effects due to stimulation of the immune system.
In many cases these effects are significant, but generally
not lethal.
Human antimicrobial factors
Defensins
There are a number antimicrobial factors made by the
mammal that protect it against pathogens. These include
many defensins. Of these, human β-definsin-1 is espe-
cially to be considered because of its location in urogeni-
tal tissues (Valora et al., [43]).
Retrocyclins that are θ-defensins and their variations have
important effect against anthrax [44]. Also, some forms of
θ-defensin and α-defensin have protective effect against
HIV-1 [45,46]. But the latter paper did not find an effect
on the mother-to-child transmission. Quinones-Mateu et
al. [47] show that human epithelial β-defensins 2 and 3
inhibit HIV-1 replication. Aono et al. [41](2006) find that
in bovines the bovine β-defensin-1 acting against E. coli
and is present in teat mucosa, vagina, ovary, and oviduct.
These references, and also MasCasullo et al. [48], allows
the possibility that I have not seen explicitly suggested
that these substances in the (female reproductive tract)
FRT act to prevent the embryo and fetus from infection by
a virus that has infected the mother. Furthermore, that
they, except for the α-defensins, have a role in the partial
protection of the newborn from infection by way of the
mother's milk.
Secretory leukocyte protease inhibitor
The secretory leukocyte protease inhibitor (SLPI) may also
be a factor that acts in prevention of HIV infection. It is
known that salivary gland tissue may have a role in sup-
pressing transmission by the oral route. Wahl et al. [49]
were able to account for the rarity of oral transmission
even though there is HIV in oral secretions. Once inside
the oral cavity, HIV is exposed to antiviral levels of SLPI,
and their data suggest that this may greatly impede infec-
tion. An extrapolation, for which there is no data, could
be that HIV might stimulate the synthesis of SLPI. A fur-
ther extension from known facts is that it may also takes
place in the genital tract and prevents secondary infection
of HIV viruses, or variants, or a broader class of STDs [50].
These suggestions could be tested.
Variable stimulation of the immune system of 
primates under different conditions
The long-term survival of the retrovirus pathogen in verte-
brate hosts depends on proper balance of the pathogen's
activity versus the hosts' immune systems. A possibly crit-
ical factor of difference between modern humans, the
Stone Age man, and the modern non-human primate
needs to be recognized here. Some of the possible differ-
ences would make the response greater or weaker, and
consequently could support or conflict with the hypothe-
sis proposed here. This balance could depend on the vari-
ety and variable extent of immune stimulation in general
and is, in addition, to the responses of these host species
to their particular varieties of retroviruses. The stimulation
of the immune system, variety of stimulations, and the
age dependency of individuals exposed to other antigens
before they are challenged by viral antigen do vary (see for
example, Esquerré M et al. [50]; Walker et al., [51]; Chir-
mule et al., [52]; Rabin et al., [53]; Miedema and Klein,
[54]; Wolensky et al., [55]). There must be marked differ-
ences in the sensitivity to antigenic stimulation of the
members of primate societies in the wild, of the humans
in developing countries, and of the humans in developed
countries. Either too much, too little, or the wrong kind of
stimulation may mean that the immune system will be
either over or under active, because of the effect on the
mucosal part of the system and, this is significant for the
theme of this paper. A slight variation may eliminate the
pathogen or fail to prevent new pathogens from entering
and supplanting the original one. The immune system
may be secondarily modified by destruction of certain
specialized T-cells in which HIV or SIV pathogen are
present. As a speculative example, young female chimpan-
zees engage in some sexual activity for some time beforeVirology Journal 2008, 5:93 http://www.virologyj.com/content/5/1/93
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they can become pregnant. If the female has been infected
with SIV for several years before she becomes fecund it
would not be surprising if she had slowly developed a
range of mucosal immune responses that would have a
protective effect on her and/or the developing fetus. This
effect might not occur if she had been infected more
immediately before pregnancy. Some aspects of the AIDS
disease process in humans are certainly similar to autoim-
mune diseases and the destruction of cells of the immune
system bearing viral or similar receptors is well known. All
that is being suggested here is that such phenomena need
be only slightly altered to give virulent disease instead of
an innocuous one in the not quite well adapted AIDS-
human pair from those of well-adapted long-term retrovi-
rus-primate pairs. In the current worldwide AIDS epi-
demic these could affect the timing of symptom onset and
the severity of debilitating disease.
At an earlier time when our blood supplies were contam-
inated, hemophiliacs were very likely to receive the AIDS
virus and become HIV seropositive. A significant point is
that their time to conversion to ARC and to fulminating
AIDS was 90% longer than other non-hemophiliac serop-
ositive persons at that time Darby et al. [56] in 1995. One
possible reason is that the medically treated hemophiliacs
were being continuously challenged and immunized
against a large variety of other substances that were
present in the various blood transfusions that they regu-
larly received. An additional factor concerning the AIDS
disease at the beginning of the world epidemic is that
when hemophilia patients were initially infected by trans-
fusion, the disease would have been started with a much
larger number of viruses than that transmitted either by
usual or unusual sexual practices or by a drug addict's re-
used needle. Consequently, their immune system was
stimulated in a way that the immune systems of normal
people infected by sexual contact are not, simply because
the intensity of the immune challenge was greater. These
facts raise the possibilities that African green monkeys are
immunologically equivalent to human hemophiliacs
receiving blood transfusions. As a result, an African green
monkey from which SIV can be isolated might naturally
have an especially effective immune system and be able to
continuously destroy a much larger proportion of retrovi-
ruses and thus limit the viremia. This could mean that the
animal would live for a long time before it might become
immunologically deficient. In any case, it will be interest-
ing to see the disease progression in fresh hemophiliac
patients that were infected by sexual transmission and not
by transfusion either while they are receiving recombinant
clotting factor without these multiple sources of diverse
immunogenic stimulation or with them.
Immune reactivity can depend on the presence of other
pathogens: Infection with mycoplasma, Herpes, Epstein-
Barr, and several other viruses may affect how HIV infec-
tion leads to an HIV-immune deficiency state. With co-
infection of such viruses, it is likely that the time at which
AIDS erupts may be sped or slowed in either the human
or monkey. This raises the possibility that a different spec-
trum of viruses and other possible diseases might influ-
ence the course of a retroviral disease. A sometimes-
symptomless retrovirus that suppresses the development
of debilitating immune deficiency might do so differently
when infecting a different host species. On the contrary,
other pathogens may trigger the emergence of the AIDS
virus from the host's chromosomes. These assorted
immunological events could greatly affect the life history
of a retrovirus in any new primate host. Consequently, it
can be argued that the AIDS virus may well have been
adapted to be 'gentle' and un-obstructive in its old host,
however, at present, those strategies do not work as well
in humans because the human pathogens are different
than the non-human primate. Because of our social
organization, our life expectancy, and our antigenic envi-
ronment, the outcome of this parasitism might well be
quite different.
A very striking observation was made fourteen years ago
[57,58](Ho et al., 1995; Wei et al., 1995; but see Pang S,
[59] and see Wain-Hobson, [60] and Miller, Antia and
Levin, [61]. The major conclusion is that the HIV viruses
grow very rapidly and are very rapidly destroyed by the
apparently healthy, but HIV positive individuals. It leaves
unanswered how much of this destruction is due directly
to the action of the host immune system versus the action
of the host when modified by the virus or responding in
other ways.
The possibility is that there are protective mechanisms
implemented by the resident HIV. A finding that is rele-
vant concerns an individual who became infected with
only one strain even though two different varieties of HIV
were transfused simultaneously into him [62].
Epidemiology of AIDS and the 'rapid' change of 
HIV
By comparing the epidemiology of HIV-I and HIV-II in
their respective parts of Africa, Ewald [21] has made the
case that the diseases vary in the virulence/gentleness scale
in a way that is correlated with the number of sexual part-
ners and the group's societal norms. This would be pre-
dicted by a game theory type calculation on the bald
assumption that the virus was omniscient without provid-
ing any suggestion of how it got to be so. Accepting his
ideas and facts as true, we can only be amazed by the
speed with which the virus can apparently change its strat-
egy and optimize the course of infection to the new con-
ditions present in a new host. I think that this means
something more significant. As an alternative to de novoVirology Journal 2008, 5:93 http://www.virologyj.com/content/5/1/93
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evolution, I suggest that this apparent rapid adaptation is
consistent with the hypothesis that STD retroviruses have
been exposed over long evolutionary times (in terms of
millions of years) to fluctuations in the behaviors of a
series of hosts (or a host under a series of very different
conditions) and have developed and retain a genetic rep-
ertoire to be able to achieve response to variations in the
host. From the molecular point of view this could allow
them to track and respond to the behavior of their current
host and conditions. Although the genetic sequences are
now known, the roles of the gene products are not fully
evident and some of the regulatory genes may have func-
tions over a long time period of years and centuries.
Why mammalian STD pathogens must protect 
their new generation of pathogens from their 
own lethal action
A careful strategy must be maintained for long term per-
sistence between the STD virus spreading from adult-to-
adult and in injuring or killing the children of an infected
host. The biology of pediatric AIDS is reviewed in Pizzo
and Wilfert [63], Remington [64], Roizman [3], Sweet and
Gibbs [65], and Kaschula [66]. Teleologically, the virus
must spare the host's young in order that they can be used
as a resource in the future, but that necessary-truth pro-
vides no mechanistic way to implement such a situation.
HTLV-I (see below) seems to have achieved this balance
by infecting most offspring of infected mothers but having
the virus grows so slowly that a child's life before puberty
is virtually unaffected. Such slow viral growth permits
propagation of the virus to virus-free individuals within a
society in which sexual contact is frequent and avoids the
usual destructive effects of vertical transmission from
mother to child. The AIDS viruses, HIV-I and HIV-II, do
not seem able to avoid injuring the children after infec-
tion occurs. But still a large proportion of the young of
infected mothers do not become infected – more than
60% and in some estimates as much as 85% for HIV-1.
Some infants, born infected, clear the HIV virus (Clerici et
al. [67]; Roques et al. [68]).
An infectious disease spreading to the next generation by
vertical transmission has advantages over pathogens dis-
seminated in other ways. The main advantage is that the
disease organism never has to survive in the environment
outside of the host. Survival of a pathogen outside of its
host in air or water takes special mechanisms. Although
the fetus is a convenient and a built-in susceptible host,
the vertical process in vertebrates has a special complexity
beyond that present in the cases when the host grows by
binary fission as bacteria do. This is because the animal
host gives birth to an immunologically ill-equipped
neonate that may not be able to survive due to damage
caused by the pathogen. This is a critical problem for an
STD's survival strategy because they generally have no
alternative propagation strategy such as survival in alter-
native hosts or persisting in the environment.
Because the newborn offspring do not have a full immu-
nity system the result is often catastrophic. This is what
happens when some pathogens, such as Herpes Type II,
Rubella, or Cytomegalovirus infect an embryo, a fetus, or
a newborn child. In these cases, without a fully protective
immune mechanism, the infection may be destructive or
lethal to the offspring and is much more severe than if the
pathogen infects an adult that has a responsive immune
system with an immune repertoire already in place.
Therefore, in many cases a would-be pathogen cannot
effectively persist via pure vertical transmission simply
because the pathogen cannot depends on its host immune
response system to bridle its growth. Viruses like Herpes,
Rubella, and Cytomegalovirus that go across uterine, vag-
inal, and placental tissue are frequently dangerous to the
fetus, but of course these viruses survive because their pri-
mary means of spreading through the population is from
an adult individual to an adult individual and are not
dependent on vertical transmission. Destroying a few chil-
dren apparently does not upset the growth success of these
viruses. However, from the viewpoint of a disease that has
elected to only use a non-virulent STD strategy, going
directly from mother to baby could be expedient,
although destructive. This must somehow be avoided,
and it apparently is often curbed by successful pathogens.
There may be a number of factors involved in the AIDS
case. One is that the AIDS virus is just not very infectious
or long-lived. Some suggestion of this comes from the fact
that AIDS is not transmitted by way of bloodsucking mos-
quitoes or efficiently through punctures of health care
workers with contaminated needles. Presumably, in the
mosquito example, this is because the virus does not last
long enough between successive blood meals of the
female mosquito. Additionally, it may not be transmitted
because infection requires large inoculums. Similarly for
the second example, the fact that HIV is quite seldom
transmitted through needle sticks to health care workers,
is possibly because most particles are inactive and many
viable particles are needed to cause infection of a healthy
health care provider.
While these could be trivial or based on molecular biolog-
ical necessity, I suggest that the virus has been selected by
evolution to extend these characters. Evidently, this is the
characteristic of particular viruses, but it also may be due
a human or primate characteristic. This can be if mankind
has habitually, over the eons, been exposed to retrovirus
type pathogens that are not AIDS. For both virus and host,
their fitness is increased in not permitting infection of the
still immunological-incompetent neonates. It may be thatVirology Journal 2008, 5:93 http://www.virologyj.com/content/5/1/93
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the low infectivity of neonates is because of some molec-
ular biological or biochemical limitation or necessity, but
in the retrovirus case it has been especially extended. This
can be argued since there are diseases that are transmitted
very efficiently by mosquito bites and by limited blood-
to-blood contact (such as Hepatitis B). So I suggest that
the HIV retrovirus is poorly infective due to innate biolog-
ical mechanisms evolved to favor the long-term goals of
its survival as an STD. This is a prediction of the model
proposed here that would have aspects that could be
experimentally pursued.
Although I will discuss below how the retrovirus human
T-cell lymphotrophic virus I (HTLV-1) avoids this diffi-
culty by known mechanisms, just how HIV perinatally
infects only a portion (15 – 30%) of children (Scott [69];
Cotton [70]) and not more is not clear. Women that
acquire HIV after delivery have a higher transmission rate
to their child by breast-feeding than do women previously
infected. We have also a hint because reducing the viremia
by zidovudine (AZT) treatment before and during the
delivery process has been shown to reduce the transmis-
sion to the child (Connor et al., [71]; Spector et al. [72]:
Rouse et al., [73]; Brossard et al., [74]) and now is routine.
However, there are reports of several children that have
been initially infected and apparently cleared themselves
of the infection (Bryson [75]); this makes it difficult to
compare different studies.
The coping strategy of HIV, HTLV-I, and HTLV-
II with their hosts
HTLV-I and HTLV-II are both retroviruses of the subclass
oncornaviruses that propagate primarily in human T lym-
phocytes. The former parasitizes the CD4-bearing helper T
cells and the latter the CD8-bearing cytotoxic T cells (See
Anderson [76]; Höllsberg and Hafler [77]; Wiktor and
Blattner [78]; Blattner [79]; White and Fenner 1994 [5]).
HIV is a retrovirus of the subclass, lentivirus, and both it
and the oncornaviruses incorporate their reversely tran-
scribed double-stranded DNA into a chromosome of a
human cell as the heart of their survival strategy. Both
classes of virus infect only a particular human cell-type
and only a cell type that continues to divide. Nerve cells
and kidney cells are not appropriate host cells because in
the adult they divide only very occasionally and therefore
the equivalent of the prophage state would never be ade-
quately created or propagated. Also an inappropriate cell
type would be a relatively rapidly growing epithelial cell
because while the stem cell remains, the sister cell is
sloughed from the skin or into the intestine and does not
remain and be propagated within the body.
The oncornaviruses, but not the lentiviruses, have a
growth pattern that allows both effective vertical transmis-
sion and horizontal transmission to new hosts. The
viruses are passed vertically to the neonate, although not
with high efficiency and not in a way that causes child-
hood death. They are also passed as a STD between sexu-
ally active individuals. In addition, in the modern world
these viruses can also be passed via needles. Before exten-
sive movements of peoples of the world population, both
HTLV viruses were geographically restricted in distribu-
tion. Although HTLV-I is now found world wide, it was
and is highly abundant in southern Japan and the Carib-
bean. It is also present in South America, west and central
Africa, India, Melanesia, and Iran. There is evidence that
similar viruses inhabit non-human primates. HTLV-II is
now highly prevalent in intravenous drug users, but is
(and presumably was) abundant in the Guaymi tribe in
Panama and, more generally, in Amer-Indians.
The strategy of both HTLV viruses in the absence of IV
drug usage and rapid movements of peoples was very
close to the 'gentle' pathogen persuasion. Both viruses
persist with little damage to their host by replicating very
slowly while being passed vertically or between adults as
an STD. Being poorly transmitted from cell-to-cell and
individual-to-individual favors the 'gentle' character, but
another feature is that they have mechanisms to cause the
hosts T-cells to replicate. Thus a syndrome, similar to that
of AIDS does not occur, resulting from depletion of T-
cells. This allows more opportunities for the virus to be
transmitted between humans. They are poorly transmissi-
ble and transmission from male to female is rare and the
transmission from female to male is very slow (at least for
HTLV-I). Though it is passed presumably in the same
three ways that HIV is passed to the neonate (i.e., in utero,
perinatally by blood-to-blood transfer, and (predomi-
nately) postnatally via mother's milk). There is little dam-
age to the child because the virus grows so slowly. Thus
the immune system has time to develop and respond to
these viruses and is even aided by the increased growth of
T-cells. Both viruses are almost perfect 'gentle' pathogens.
However, the current longevity of the human host is suffi-
cient to cause problems (see White and Fenner, [5]). For
example, there is the occasional generation by HTLV-I of
an adult T-cell leukemia (ATL). Less frequently T-cell
chronic lymphocytic leukemia, non-Hodgkin's lym-
phoma, mycosis fungoides, and Sezary syndrome arise.
HTLV-II has not been adequately studied, but appears to
be even more 'gentle', and only very rarely causes certain
diseases: i.e., glomerular nephritis and HTLV-associated
myelopathy.
Molecular biological information is mainly available for
HTLV-I, but the studies of the rex and tax genes are rele-
vant to the trick that this virus has of alternately stimulat-
ing T-cell growth and then subsequently switching to the
HTLV-I replication mode (Yoshida et al. [80]; Hinrichs et
al. [81]). Of particular importance to the major thesis ofVirology Journal 2008, 5:93 http://www.virologyj.com/content/5/1/93
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this speculative paper is that the rex gene of HTLV-I inter-
acts with the rev gene of HIV and this may suggest that the
human virus may act to protect its host against some other
pathogen.
How HIV is 'Gentle' to its host
Some of the methods that HIV uses to be lysogenic and
spread from host to host are obvious from its generally
known biology (Daniel et al. [82]). Most obvious is that a
retrovirus, in principle, would only be able to grow as the
provirus in concert with a reproducing cell. HIV for exam-
ple, can enter a quiescent cell and give rise to DNA prod-
ucts, but the DNA is only integrated after activation of the
cell and replication of its chromosome (Zack et al., [83];
Stevenson et al., [84]; Haase et al., [85]). But the sole use
of CD4 as a target receptor limits its opportunity to grow
and reproduce. Maintenance of the latent state is another
essential factor that keeps the virus from rapidly destroy-
ing the immune system. This is in addition to the host's
immune system acting as an essential safeguard for viral
long-term propagation within the host and transmission
into other hosts.
Conclusion
(a) The evolutionary mechanisms that maintain the non-
virulent state of a pathogen are of high interest. Since
there are a large number of mild pathogens in nature and
in spite of the selective advantage that a virulent mutant
would temporarily have, the 'gentle' pathogen state does
arise and does persist. A proposed mechanism for this, not
involving group or kin selection, has been made Koch
[86]. This new model is that the pathogen protects itself
(and incidentally its host) against other similar or identi-
cal pathogens arriving subsequently and that this gener-
ates and maintains the 'gentle' state.
(b) It is argued that pathogens that depend on humans as
a resource faced a much different problem during the
hunter/gatherer Stone Age than now, and at this early time
the spectrum of viruses could be expected to have been
largely STDs because of the sparse availability of hosts.
Almost of necessity many pathogens must have been 'gen-
tle' because the interactions between social groups were
infrequent. Before moving to humans from the primates,
HIV must have been gentle to its nonhuman primate host,
and possibly it has not had time to readjust to become
gentle its new host.
(c) Being a 'gentle' pathogen requires elaborate controls to
self-limit growth of its host. Persistence over long times of
a sexually transmitted disease depends, therefore, on
growth inhibitory mechanisms in part coded by the virus,
but frequently dependent on host function. The host
immune system limits the viremia and viral encoded
mechanisms and may act to modulate the immune
response and act in other ways to control and limit viral
growth. It can be assumed that the lentiviruses of nonhu-
man primates, such as SIV are adapted to a low rate of ver-
tical transmission because of the devastating action of
many viruses on neonates due to the latter's underdevel-
oped immune system. These may be avoided by slow
growth. HIV is transmitted to offspring in utero, perina-
tally, or via breast-feeding, but the transmission is less effi-
cient than for some other viral diseases. This suggests that
host and viral mechanisms restrict vertical transmission or
its effects for the case of HIV for the fetus and the neonate.
(d) The HIV retrovirus strategy depends on selectively
infecting a restricted class of cells, mainly the CD4+ or
CD8+ T helper cells. These and other T and B cells happen
to be nearly the only suitable cells, a priori, in an mammal;
these uniquely continue to grow, replicate, and divide to
form progeny that remaining inside the host. Such a type
of cell is the necessary condition for the strategy of retro-
viral growth. Thus these host cells are different than other
cells of the body that only divide rarely or of cells that are
shed from the animal such as skin and intestinal epithe-
lium.
(e) It is proposed that the response of the mucosal part of
the host immune system is not only the key factor to the
prevention of many viral infections, but also it is to pre-
vent or reduce the infection of the offspring of an infected
female. This is because the selection for an ability to elicit
an effective mucosal immune response by the products
generated by the virus that would block secondary infec-
tion and is in the best interests of the virus, therefore. But
it also makes the resident pathogen less destructive to its
host and its host's progeny. I suggest that the role of
mucosal immunological response and other defensive
responses is critical for the biology of the STD retroviruses.
(f) The important link in the STD lifestyle as typified by
the HIV/human interaction is that the virus must work
against itself under conditions in which the hosts are at a
premium and must somehow protect the fetus and
neonate. It is the fact that such protection is manifest even
with HIV infection of humans. About 85% of the off-
spring of HIV-infected mother are not HIV infected and in
simian viruses in wild monkeys the number may be closer
to 100%. Compared with some other viral diseases, this
suggests that specific immune protection of the fetus peri-
natally does occur.
(g) The change from the forebears of HIV, presumed to be
a 'gentle' virus of its non-human primates, to the devastat-
ing human virus of AIDS is mostly because the new host
of the virus lives much longer than its previous host.
Added to this are the factors due to the human host's
social behavior, most notably the extensive movements ofVirology Journal 2008, 5:93 http://www.virologyj.com/content/5/1/93
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humans from place to place. Also HIV appears very
ungentle now because of its spread to a greatly expanded
habitat, and because of the sociology due to the homosex-
ual involvement and intravenous drug use.
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